Evidence map›Paper›PMID 17030744›Full record

ReviewNeurology2006

Treatment of neurocysticercosis: current status and future research needs.

T E Nash, G Singh, A C White, V Rajshekhar, J A Loeb, J V Proaño, O M Takayanagui, A E Gonzalez, J A Butman, C DeGiorgio and 9 more

Open access · greenAbstract readReview
In one paragraph

Review in Neurology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 182 citations in OpenAlex.

  1. Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Trial
  2. Trial
  3. Trial
  4. Three decades of neurocysticercosis mandatory notification in a Brazilian endemic region: clinical evolution and severity patterns.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  5. Article
  6. Article
  7. Isolated Spinal Cord Neurocysticercosis.Journal of radiology case reports · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Lumbar spinal intradural neurocysticercosis: A case report.Experimental and therapeutic medicine · 2017
    Article
  17. Article
  18. Article
  19. Taenia crassiceps injection into the subarachnoid space of rats simulates radiological and morphological features of racemose neurocysticercosis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017
    Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

T E NashLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA. tnash@niaid.nih.gov
G Singh
A C White
V Rajshekhar
J A Loeb
J V Proaño
O M Takayanagui
A E Gonzalez
J A Butman
C DeGiorgio
O H Del Brutto
A Delgado-Escueta
C A W Evans
R H Gilman
S M Martinez
M T Medina
E J Pretell
J Teale
H H Garcia
Christian Medical College, Vellore · IN

Funding

Studies of neurocysticercosis and animal cestode infectionsZIAAI000846 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NASH, THEODORE · 2009 to 2020
$9.5M
Studies of neurocysticercosis and animal cestode infectionsZ01AI000846 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI NASH, THEODORE · 1999 to 2008
$831k
Wellcome Trust 057434
6 · The paper itself

Abstract

Here we put forward a roadmap that summarizes important questions that need to be answered to determine more effective and safer treatments. A key concept in management of neurocysticercosis is the understanding that infection and disease due to neurocysticercosis are variable and thus different clinical approaches and treatments are required. Despite recent advances, treatments remain either suboptimal or based on poorly controlled or anecdotal experience. A better understanding of basic pathophysiologic mechanisms including parasite survival and evolution, nature of the inflammatory response, and the genesis of seizures, epilepsy, and mechanisms of anthelmintic action should lead to improved therapies.

Indexed as

AnticonvulsantsAntiplatyhelmintic AgentsBiomedical ResearchForecastingHumansNeeds AssessmentNeurocysticercosisNeurosurgical ProceduresPractice Guidelines as TopicPractice Patterns, Physicians'AnticonvulsantsAntiplatyhelmintic Agents

Identifiers

PMID17030744
PMCPMC2923067
OpenAlexW2169483387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.